Day: April 23, 2025

SANTA CLARA, CA , April 23, 2025 (GLOBE NEWSWIRE) — Andes Technology (TWSE: 6533; SIN: US03420C2089; ISIN: US03420C1099), the leading supplier of high-efficiency, low-power 32/64-bit RISC-V processor cores and Founding Premier member of RISC-V International, in collaboration with Imagination Technologies, today announces the successful demonstration of Android 15 (Vanilla Ice Cream) running on a high-performance RISC-V-based hardware system. This achievement highlights the growing potential of RISC-V as a platform for rich operating systems and advanced graphical applications. The demonstration leverages Andes’ Voyager Board, powered by its Qilai SoC, in combination with Imagination’s GPU integrated within a graphics card. Together, the companies are showcasing a highly capable, fully operational Android system built on open hardware...

PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext – FR0010557264 – AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML). AB8939 had already obtained orphan drug designation from the US Food and Drug Administration (FDA) in AML. Granting of this orphan drug status in the EU is a significant milestone because it means that the COMP considered that AB8939 offers a significant benefit to people suffering from this condition in addition to existing treatments. Indeed, the criteria to obtain orphan drug designation at EMA differ...

Selected nonprofit organizations are accelerating digital equity and powering the future of work in Greece, Indonesia, Nigeria, and Spain for disconnected communities News Highlights:Eight nonprofit organizations in Greece, Indonesia, Nigeria, and Spain selected for the 2025 Digital Equity Accelerator. Organizations are serving disconnected adolescents and adults through digital skills training, education access, and other community-driven initiatives. Each nonprofit will receive $100,000 of HP technology and solutions, capacity-building cash grants, and six–months of training and programming to support scale. In its first three years, the Accelerator helped 27 participating organizations expand their reach by more than 9 million people. The Digital Equity Accelerator, a joint initiative of HP Inc. and the HP Foundation, helps power...

Q1 2025 REVENUES In a complex economic environment, SYNERGIE generated sales of €757.5 million in the first quarter of 2025, up +0.8% in € m Q1 2025 Q1 2024 VariationInternational 463.7 447.9 +3.5%France 293.8 303.5 -3.2%Total 757.5 751.4 +0.8%SYNERGIE reported quarterly sales of €757.5 million, up +0.8% on previous year (-1.2% on a like-for-like basis). International business accounted for 61.2% of sales in the first quarter, compared to 59.6% in 2024. International sales grew by +3.5% in Q1 2025, driven by our acquisitions, which generated €14.3 million, and by an organic growth of +0.1%. Due to international political uncertainties and the economic difficulties faced by companies the downturn in certain markets in Northern and Eastern Europe weighed on this region’s performance (-2.8% on a like-for-like basis)....

NACON’S REVOLUTION X UNLIMITED AVAILABLE NOW IN STORES Lesquin (France), April 23 2025 – NACON, a world leader in gaming accessories, is pleased to announce that its new Revolution X Unlimited (RXU) controller is now available. Particularly suited for shooting games, this Designed for Xbox licensed wireless controller offers unrivaled precision, responsiveness and comfort, whether you’re playing on Xbox Series X|S* or PC. It is now available from nacongaming.com at the recommended retail price of 199.90€. Watch the Revolution X Unlimited launch trailer here  With over 10 years’ expertise in research and development, NACON’s team of engineers has created the RXU, a concentrated blend of technology, unique features and a range of additional game modes. More than just a controller, the RXU boasts enhanced durability, unique...

SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT.Presenter Abstract Title Presentation DetailsThorvardur Halfdanarson [212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and...